Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Biomed Pharmacother ; 174: 116539, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38615610

RESUMEN

This study aimed to investigate the effects of the calpain inhibitor N-Acetyl-Leu-Leu-norleucinal (ALLN) on neuroapoptotic cell damage caused by Copper Oxide Nanoparticles (CuO-NP) and exacerbation of damage through brain ischemia/reperfusion (I/R) in a rat model. Male Wistar Albino rats (n=80) were divided into eight groups: Control, I/R, CuO-NP, CuO-NP+I/R, I/R+ALLN, CuO-NP+ALLN, CuO-NP+I/R+ALLN, and DMSO. Biochemical markers (MBP, S100B, NEFL, NSE, BCL-2, Cyt-C, Calpain, TNF-α, Caspase-3, MDA, and CAT) were measured in serum and brain tissue samples. Histological examinations (H&E staining), DNA fragmentation analysis (TUNEL) were performed, along with Caspase-3 assessment. The ALLN-treated groups exhibited significant improvements in biochemical markers and a remarkable reduction in apoptosis compared to the damaged groups (CuO-NP and I/R). H&E and Caspase-3 staining revealed damage-related morphological changes and reduced apoptosis in the ALLN-treated group. However, no differences were observed among the groups with TUNEL staining. The findings suggest that ALLN, as a calpain inhibitor, has potential implications for anti-apoptotic treatment, specifically in mitigating neuroapoptotic cell damage caused by CuO-NP and I/R.


Asunto(s)
Calpaína , Cobre , Modelos Animales de Enfermedad , Glicoproteínas , Leupeptinas , Ratas Wistar , Daño por Reperfusión , Animales , Masculino , Daño por Reperfusión/patología , Daño por Reperfusión/tratamiento farmacológico , Cobre/toxicidad , Calpaína/metabolismo , Calpaína/antagonistas & inhibidores , Ratas , Apoptosis/efectos de los fármacos , Nanopartículas , Oligopéptidos/farmacología , Isquemia Encefálica/tratamiento farmacológico , Isquemia Encefálica/patología , Isquemia Encefálica/inducido químicamente , Encéfalo/efectos de los fármacos , Encéfalo/patología , Encéfalo/metabolismo , Fármacos Neuroprotectores/farmacología , Caspasa 3/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA